Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This study is a first‐in‐human phase I randomised, double‐blind, placebo‐controlled, evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single (IV and SC) and Multiple (IV only) Ascending Doses of OSE‐127 in Healthy Subjects.
Epistemonikos ID: 6bff181e51b8c3711321b1a82756ae76d199fd3b
First added on: May 22, 2024